

Dicot Pharma presents at Stora Aktiedagarna on November 26

Uppsala, Sweden, November 13, 2025. Dicot Pharma announces today that CEO Elin Trampe will present the latest progress in the development of the drug candidate LIB-01 and the company's strategy moving forward during Aktiespararna's event Stora Aktiedagarna in Stockholm on November 25–27.

The presentation will take place on Wednesday, November 26, at 1:30 p.m. CET and can be watched live through the link below:

<https://invitepeople.com/public/events/ca68015fc8/pages/cc21d41276>

The presentation will also be available on the company's website after the event:

<https://www.dicotpharma.com/media/filmer/>

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 17,400 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.